Cartherics’ COO, Dr Ian Nisbet recently joined Xtalks’ Life Science Podcast to discuss Cartherics’ vision for next generation cell therapies.
He discussed how Cartherics’ platform is building an effectively unlimited supply of CAR NK cells and exploring treatments for underserved conditions like cancer and endometriosis. Dr Nisbet also reflects on his biotech leadership […]
Cartherics is proud to share that our CEO, Professor Alan Trounson, was recently interviewed on 10 News+ by journalists Amelia Brace and Denham Hitchcock.
In the interview, Prof. Trounson provided an in-depth look at Cartherics’ world-first immunotherapies and how this innovative science is shaping the future of treatment for some of the most difficult-to-treat diseases.
Our lead […]
Cartherics is pleased to announce that Mathew Tiedemann has officially completed his PhD, a major milestone in an already impressive scientific journey! His thesis titled, ‘Developing a Clinically Translatable iPSC-derived Immunotherapy’ focused on designing clinically relevant methods to create billions of gene-edited blood cells from stem cells to better detect and destroy ovarian cancer.
Mat’s key […]
In the competitive biotech landscape, groundbreaking science alone isn’t enough. As highlighted in a recent article by Dynamic Business, Cartherics’ strategic appointment of U.S. biotech executive Laurence Nore underscores the critical importance of navigating the complexity of healthcare markets. Laurence emphasises that many promising biotech firms falter not due to flawed science but because they […]
In the lead-up to BIO, Cartherics’ COO, Dr Ian Nisbet was interviewed by BioSpectrum Asia to discuss the company’s innovative approach to cell therapy development. He discusses the transformative potential of CAR-NK cell therapies in treating solid tumours and endometriosis. These engineered natural killer cells, derived from iPSCs, are designed to target and eliminate cancer […]
Cartherics’ appointment of Laurence Nore underscores a growing trend with global implications.
As global demand for biotechnology products and services continues to grow, innovation in the industry is becoming increasingly globalised. Cartherics Pty Ltd, a Melbourne-based biotech company pioneering cell-based immunotherapies, recently announced the appointment of U.S. life sciences executive Laurence Nore to […]
Today on World Ovarian Cancer Day, we are proud to share the powerful story of Heather Hawkins – ovarian cancer survivor, global marathon runner, patient advocate, and a valued Board Advisor at Cartherics.
After being diagnosed with ovarian cancer in 2007, Heather transformed her experience into a mission of awareness, action, and hope. Her survivorship, combined […]
Melbourne, Australia, 16 April 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, is pleased to announce the appointment of Prof. Bryan R.G. Williams […]
Cartherics is pleased to announce that it has made several strategic new appointments to enhance its scientific and manufacturing teams, aligning with the company’s commitment to advancing its growing pipeline of innovative therapies. These new additions are expected to bring in diverse expertise, reinforcing the company’s capabilities in both research and development as well […]
As we reflect on 2024, it’s clear that this year has been a defining chapter in Cartherics’ 10-year history. We’ve experienced significant milestones, overcome challenges, and made bold strides toward advancing our mission. The work on ovarian cancer has progressed with the autologous CAR-T product under preclinical evaluation by the Peter MacCallum Cancer Centre, […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
